Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to TestingGlobeNewsWire • 07/11/24
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the ElectionGlobeNewsWire • 06/24/24
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment ToolGlobeNewsWire • 06/03/24
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applicationsGlobeNewsWire • 05/30/24
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual MeetingGlobeNewsWire • 05/23/24
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate CancerGlobeNewsWire • 05/16/24
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDAGlobeNewsWire • 05/07/24
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict BusinessGlobeNewsWire • 05/07/24
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024GlobeNewsWire • 04/30/24
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/24/24
Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorGlobeNewsWire • 04/17/24
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal ScreenGlobeNewsWire • 04/16/24